Urea Cream Prevention for Capecitabine Associated Hand Foot Syndrome

Launched by MAHIDOL UNIVERSITY · Apr 21, 2022

Keywords

ClinConnect Summary

The patients who is planned to receive capecitabine for at least 3 cycles were enrolled in the study. The patients were randomized to receive 10% urea cream or standard measure. The patients were followed until the end of capecitabine treatment. The patients reported their symptoms of HFS and other adverse events (AE) before starting new cycle of capecitabine. Physician record of HFS and other AE, dose modification of capecitabine and compliance were extracted. We will report incidence of any HFS, \> grade 3 HFS, capecitabine interruption or delay or discontinuation and time to develop HFS ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - patients who has plan to receive capecitabine at the dosage of at least 2000 mg/m2 D1-14 every 21 days for at least 3 cycles
• Exclusion Criteria:
• • preexisting neuropathy which was severe than grade 2
• • history of allergy to urea cream
• • patients with previous use of capecitabine 2000 mg/m2
• • patients who has prior routinely used of urea cream